Kamada Ltd. (KMDA)

Market Cap	344.88M
Revenue (ttm)	158.38M
Net Income (ttm)	15.71M
Shares Out	57.49M
EPS (ttm)	0.27
PE Ratio	21.95
Forward PE	17.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,574
Open	5.94
Previous Close	5.85
Day's Range	5.83 - 5.99
52-Week Range	4.74 - 6.53
Beta	0.20
Analysts	Strong Buy
Price Target	14.50 (+145.76%)
Earnings Date	Nov 13, 2024

About KMDA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMR...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 378
• Stock Exchange: NASDAQ
• Ticker Symbol: KMDA
• Website: https://www.kamada.com

Analyst Forecast

According to 2 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 145.76% from the latest price.

Price Target

$14.5

(145.76% upside)

Analyst Consensus: Strong Buy